<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37489616</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Annals of medicine</Title><ISOAbbreviation>Ann Med</ISOAbbreviation></Journal><ArticleTitle>Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>2238600</StartPage><MedlinePgn>2238600</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2238600</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2023.2238600</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Low-dose interleukin-2 (IL-2) regulates the homeostasis of CD4<sup>+</sup> T cells by modulating the proportions of effector and regulatory T cells, thus reducing disease activity in patients with systemic lupus erythematosus (SLE). However, to date, no research has been carried out on the efficacy of low-dose IL-2 for treating autoimmune thyroid disease (AITD). The aim of this study was to observe the effects of IL-2 on AITD patients with concurrent SLE, and explore potential mechanism of action.</AbstractText><AbstractText Label="METHODS">A retrospective analysis was conducted on 29 SLE patients with concurrent AITD. Among them, 11 patients were in IL-2 therapy group and 18 patients without IL-2 treatment were considered as control group. Two groups had similar disease activities and were treated with comparable regular strategy. Free triiodothyronine (FT3), free thyroxine (FT4), thyroxine(T4), triiodothyronine(T3), thyroid stimulating hormone (TSH), thyroglobulin antibody (TG-Ab), thyroid peroxidase antibody (TPO-Ab) levels and immune cell subgroups were measured.</AbstractText><AbstractText Label="RESULTS">After receiving low-dose IL-2 therapy, the TG-Ab and TPO-Ab levels decreased drastically (TG-Ab <i>p</i>&#x2009;=&#x2009;0.008, TPO-Ab <i>p</i>&#x2009;=&#x2009;0.007), and the majority of the AITD patients became seronegative, while there was no discernible change in control group. In IL-2 group, percentage of CD4<sup>+</sup> T cells showed a significant increase after treatment (<i>p</i>&#x2009;=&#x2009;0.029), with an upward trend in the ratio of regulatory T (Treg) cells to follicular helper T (Tfh) cells (Treg/Tfh). The percentage as well as absolute count of B cells demonstrated a decreasing trend.</AbstractText><AbstractText Label="CONCLUSION">Low-dose IL-2 may downregulate the levels of TG-Ab and TPO-Ab by modulating the immune balance of Treg/Tfh and B-cells, providing new avenue for clinical treatment of AITD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Naidi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yuebo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Gong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med</MedlineTA><NlmUniqueID>8906388</NlmUniqueID><ISSNLinking>0785-3890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical><Chemical><RegistryNumber>06LU7C9H1V</RegistryNumber><NameOfSubstance UI="D014284">Triiodothyronine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014284" MajorTopicYN="N">Triiodothyronine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="Y">Thyroid Diseases</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>Low-dose IL-2 could decrease the levels of TG-Ab and TPO-Ab in AITD with concurrent SLE patients.Low-dose IL-2 may regulate Treg/Tfh balance and B-cells to ameliorate TG-Ab and TPO-Ab.Low-dose IL-2 provides a new avenue for AITD clinical treatment.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Low-dose interleukin-2</Keyword><Keyword MajorTopicYN="N">autoimmune thyroid disease</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors report no declarations of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37489616</ArticleId><ArticleId IdType="pmc">PMC10392266</ArticleId><ArticleId IdType="doi">10.1080/07853890.2023.2238600</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonelli A, Ferrari SM, Corrado A, et al. . Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):1&#x2013;9. doi:10.1016/j.autrev.2014.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.10.016</ArticleId><ArticleId IdType="pubmed">25461470</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeod DS, Cooper DS.. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252&#x2013;265. doi:10.1007/s12020-012-9703-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-012-9703-2</ArticleId><ArticleId IdType="pubmed">22644837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce SH, Leech NJ.. Toward precise forecasting of autoimmune endocrinopathy. J Clin Endocrinol Metab. 2004;89(2):544&#x2013;547. doi:10.1210/jc.2003-032142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-032142</ArticleId><ArticleId IdType="pubmed">14764759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Li CW, Hammerstad SS, et al. . Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82&#x2013;90. doi:10.1016/j.jaut.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.07.009</ArticleId><ArticleId IdType="pmc">PMC4628844</ArticleId><ArticleId IdType="pubmed">26235382</ArticleId></ArticleIdList></Reference><Reference><Citation>Benvenga S, Elia G, Ragusa F, et al. . Endocrine disruptors and thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101377. doi:10.1016/j.beem.2020.101377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2020.101377</ArticleId><ArticleId IdType="pubmed">32081544</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DS, Biondi B.. Subclinical thyroid disease. Lancet. 2012;379(9821):1142&#x2013;1154. doi:10.1016/s0140-6736(11)60276-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(11)60276-6</ArticleId><ArticleId IdType="pubmed">22273398</ArticleId></ArticleIdList></Reference><Reference><Citation>Biondi B, Cooper DS.. Subclinical hyperthyroidism. N Engl J Med. 2018;378(25):2411&#x2013;2419. doi:10.1056/NEJMcp1709318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1709318</ArticleId><ArticleId IdType="pubmed">29924956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari SM, Fallahi P, Elia G, et al. . Thyroid autoimmune disorders and cancer. Semin Cancer Biol. 2020;64:135&#x2013;146. doi:10.1016/j.semcancer.2019.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2019.05.019</ArticleId><ArticleId IdType="pubmed">31158464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralli M, Angeletti D, Fiore M, et al. . Hashimoto&#x2019;s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102649</ArticleId><ArticleId IdType="pubmed">32805423</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartalena L. Diagnosis and management of graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724&#x2013;734. doi:10.1038/nrendo.2013.193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2013.193</ArticleId><ArticleId IdType="pubmed">24126481</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan SM, Rapoport B.. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35(1):59&#x2013;105. doi:10.1210/er.2013-1055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2013-1055</ArticleId><ArticleId IdType="pmc">PMC3895862</ArticleId><ArticleId IdType="pubmed">24091783</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TJ, Heged&#xfc;s L.. Graves&#x2019; disease. N Engl J Med. 2016;375(16):1552&#x2013;1565. doi:10.1056/NEJMra1510030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1510030</ArticleId><ArticleId IdType="pubmed">27797318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zhang L, Chen H, et al. . Analysis of regulatory T cell subsets and their expression of helios and PD-1 in patients with hashimoto thyroiditis. Int J Endocrinol. 2019;2019:5368473. doi:10.1155/2019/5368473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5368473</ArticleId><ArticleId IdType="pmc">PMC6535823</ArticleId><ArticleId IdType="pubmed">31214258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks D, Baxter B, Campbell BCV, et al. . Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13:612&#x2013;632. doi:10.1177/1747493018778713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1747493018778713</ArticleId><ArticleId IdType="pubmed">29786478</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugen BR, Alexander EK, Bible KC, et al. . 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1&#x2013;133. doi:10.1089/thy.2015.0020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId><ArticleId IdType="pmc">PMC4739132</ArticleId><ArticleId IdType="pubmed">26462967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollowell JG, Staehling NW, Flanders WD, et al. . Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489&#x2013;499. doi:10.1210/jcem.87.2.8182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem.87.2.8182</ArticleId><ArticleId IdType="pubmed">11836274</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan FA, Al-Jameil N, Khan MF, et al. . Thyroid dysfunction: an autoimmune aspect. Int J Clin Exp Med. 2015;8:6677&#x2013;6681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509150</ArticleId><ArticleId IdType="pubmed">26221205</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderpump MP, Tunbridge WM, French JM, et al. . The incidence of thyroid disorders in the community: a twenty-year follow-up of the whickham survey. Clin Endocrinol (Oxf). 1995;43(1):55&#x2013;68. doi:10.1111/j.1365-2265.1995.tb01894.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.1995.tb01894.x</ArticleId><ArticleId IdType="pubmed">7641412</ArticleId></ArticleIdList></Reference><Reference><Citation>Biondi B, Cappola AR, Cooper DS.. Subclinical hypothyroidism: a review. Jama. 2019;322(2):153&#x2013;160. doi:10.1001/jama.2019.9052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.9052</ArticleId><ArticleId IdType="pubmed">31287527</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh SB, Aw TC.. Laboratory testing in thyroid Conditions - Pitfalls and clinical utility. Ann Lab Med. 2019;39(1):3&#x2013;14. doi:10.3343/alm.2019.39.1.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2019.39.1.3</ArticleId><ArticleId IdType="pmc">PMC6143469</ArticleId><ArticleId IdType="pubmed">30215224</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Voell M, Rahlff I, et al. . Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (hashimoto&#x2019;s thyroiditis) treated with levothyroxine. Thyroid. 2008;18(7):755&#x2013;760. doi:10.1089/thy.2008.0008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2008.0008</ArticleId><ArticleId IdType="pubmed">18631004</ArticleId></ArticleIdList></Reference><Reference><Citation>El Fassi D, Banga JP, Gilbert JA, et al. . Treatment of graves&#x2019; disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130(3):252&#x2013;258. doi:10.1016/j.clim.2008.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.09.007</ArticleId><ArticleId IdType="pubmed">18964302</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao S, Yu X, Shen L.. Autoimmune thyroid diseases and Th17/treg lymphocytes. Life Sci. 2018;192:160&#x2013;165. doi:10.1016/j.lfs.2017.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2017.11.026</ArticleId><ArticleId IdType="pubmed">29158050</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Yuan J, Zhu YF, et al. . Imbalance of Th17/treg in different subtypes of autoimmune thyroid diseases. Cell Physiol Biochem. 2016;40(1&#x2013;2):245&#x2013;252. doi:10.1159/000452541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452541</ArticleId><ArticleId IdType="pubmed">27855396</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue H, Yu X, Ma L, et al. . The possible role of CD4+CD25(high)Foxp3+/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with hashimoto thyroiditis. Endocrine. 2015;50(3):665&#x2013;673. doi:10.1007/s12020-015-0569-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-015-0569-y</ArticleId><ArticleId IdType="pubmed">25771887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossowski A, Moniuszko M, D&#x105;browska M, et al. . Lower proportions of CD4&#x2009;+&#x2009;CD25(high) and CD4&#x2009;+&#x2009;FoxP3, but not CD4&#x2009;+&#x2009;CD25&#x2009;+&#x2009;CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases. Autoimmunity. 2013;46(3):222&#x2013;230. doi:10.3109/08916934.2012.751981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2012.751981</ArticleId><ArticleId IdType="pubmed">23249428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WZ, Morris GP, Kong YC.. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother. 2004;53(2):73&#x2013;78. doi:10.1007/s00262-003-0444-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-003-0444-1</ArticleId><ArticleId IdType="pubmed">14610619</ArticleId></ArticleIdList></Reference><Reference><Citation>Verginis P, Li HS, Carayanniotis G.. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4&#x2009;+&#x2009;CD25+ T cells. J Immunol. 2005;174(11):7433&#x2013;7439. doi:10.4049/jimmunol.174.11.7433.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.7433</ArticleId><ArticleId IdType="pubmed">15905592</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazuela M, Garc&#xed;a-L&#xf3;pez MA, Figueroa-Vega N, et al. . Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91(9):3639&#x2013;3646. doi:10.1210/jc.2005-2337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2005-2337</ArticleId><ArticleId IdType="pubmed">16804051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha B, Huang X, Lin J, et al. . Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease. J Clin Lab Anal. 2014;28(3):249&#x2013;254. doi:10.1002/jcla.21674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.21674</ArticleId><ArticleId IdType="pmc">PMC6807618</ArticleId><ArticleId IdType="pubmed">24478186</ArticleId></ArticleIdList></Reference><Reference><Citation>Glick AB, Wodzinski A, Fu P, et al. . Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid. 2013;23(7):871&#x2013;878. doi:10.1089/thy.2012.0514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2012.0514</ArticleId><ArticleId IdType="pmc">PMC3704106</ArticleId><ArticleId IdType="pubmed">23379353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Chen Y, Zhao Q, et al. . Increased circulating Tfh17 and PD-1(+)tfh cells are associated with autoantibodies in hashimoto&#x2019;s thyroiditis. Autoimmunity. 2018;51(7):352&#x2013;359. doi:10.1080/08916934.2018.1516761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2018.1516761</ArticleId><ArticleId IdType="pubmed">30345813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ren M, Zeng H, et al. . Elevated follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of graves&#x2019; disease. Immunol Res. 2015;62(2):163&#x2013;174. doi:10.1007/s12026-015-8647-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-015-8647-z</ArticleId><ArticleId IdType="pubmed">25894310</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas AK, Trotta E, D RS, et al. . Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):1&#x2013;8. doi:10.1126/sciimmunol.aat1482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aat1482</ArticleId><ArticleId IdType="pubmed">29980618</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang X, Wei Y, et al. . Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991&#x2013;993. doi:10.1038/nm.4148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4148</ArticleId><ArticleId IdType="pubmed">27500725</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang R, Shao M, et al. . Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141&#x2013;149. doi:10.1136/annrheumdis-2019-215396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215396</ArticleId><ArticleId IdType="pmc">PMC6937406</ArticleId><ArticleId IdType="pubmed">31537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenzwajg M, Lorenzon R, Cacoub P, et al. . Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209&#x2013;217. doi:10.1136/annrheumdis-2018-214229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214229</ArticleId><ArticleId IdType="pubmed">30472651</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao M, Li Y, Huang B, et al. . Treatment of active idiopathic inflammatory myopathies by Low-Dose interleukin-2: a prospective cohort pilot study. Rheumatol Ther. 2021;8(2):835&#x2013;847. doi:10.1007/s40744-021-00301-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00301-3</ArticleId><ArticleId IdType="pmc">PMC8217480</ArticleId><ArticleId IdType="pubmed">33852146</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale G, Lupoli G, Guarrasi R, et al. . Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2013;98(10):E1567&#x2013;1574. doi:10.1210/jc.2013-1443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2013-1443</ArticleId><ArticleId IdType="pubmed">23884781</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Quintero B, Yazbeck C, Sweeney LB.. Thyroiditis: evaluation and treatment. Am Fam Physician. 2021;104:609&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">34913664</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenstein Z, Engelsman E, Weiss M, et al. . Production of and response to interleukin-2 in graves&#x2019; disease. J Clin Immunol. 1988;8(5):349&#x2013;355. doi:10.1007/bf00917150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00917150</ArticleId><ArticleId IdType="pubmed">2972741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>